HI homepage

Thumbnail
A pragmatic framework for evaluating the financial impact of radiology AI

A new analysis offers insight into how the decision to implement AI can affect an organization’s clinical efficiency and financial health, suggesting these decisions do not always offer the ROI vendors promise.

mergers and acquisitions M&A partnerships
Radiation oncology providers form nonprofit network in bid to preserve independence

"Physicians should not have to surrender their independence to survive, and families deserve care close to home," those involved with the new Anoma Cancer Collective say. 

healthcare value value-based care money dollar
Are imaging-cautious ordering physicians a ‘dying breed’?

David Canes, MD, a Massachusetts-based urologist, posed the question on social media July 8, garnering over 100 responses from radiologists and other physicians. 

money court scale of justice ruling legal settlement
Radiologist pushes back against snowbird couple’s claim he missed signs of a stroke

Attorneys for radiologist Eric J. Sax, MD, MBA, and MaineHealth contend the lawsuit has circumvented crucial pre-litigation requirements established in the state. 

artificial intelligence healthcare industry digest
Generative AI use in radiology manuscript writing has more than doubled

Disclosing the utilization of AI is not enough to ensure the integrity of manuscripts, the editor-in-chief of a prominent radiology journal cautions.

Thumbnail
Radiology solutions provider Leo Cancer Care rakes in $65M

The company intends to put the funds toward scaling the manufacturing of its collection of upright radiology solutions, which include proton therapy, photon therapy and other imaging offerings.

Around the web

RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model. 

 

Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.

A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.